Joubert Syndrome

Joubert Syndrome is a rare genetic condition that affects the development of the brain, specifically an area called the cerebellum, which controls balance and coordination. Children born with this condition often have low muscle tone (hypotonia), developmental delays, and difficulty coordinating their movements (ataxia). They may also have unusual breathing patterns, such as breathing very fast or stopping breathing for short periods, especially when they are babies. A key feature that doctors look for to diagnose Joubert Syndrome is a specific shape in the brain seen on an MRI scan, which is called the "molar tooth sign" because it looks like a tooth. In addition to affecting the brain, Joubert Syndrome can also impact other parts of the body, including the eyes, kidneys, and liver. Many individuals with this condition develop vision problems due to a condition called retinal dystrophy, where the light-sensitive layer at the back of the eye (the retina) slowly breaks down. This can cause difficulty seeing in the dark, a narrowing of the field of vision, and in some cases, severe vision loss or blindness from a young age. Other eye issues like crossed eyes (strabismus), droopy eyelids (ptosis), and jerky eye movements (nystagmus) are also common. Because Joubert Syndrome can affect multiple organs, it is important for patients to have regular check-ups with a team of different doctors, including eye specialists, kidney doctors, and neurologists. While there is currently no cure for the condition, treatments like physical, occupational, and speech therapy can help children reach their full potential. Regular monitoring of the eyes, kidneys, and liver is crucial to catch and manage any complications early, helping to improve the quality of life for individuals with Joubert Syndrome.

Condition category: Syndromic IRD

Prevalence: 1 in 80,000 to 1 in 100,000

Inheritance patterns: Autosomal Recessive

Age of onset: Birth to early childhood

Clinical overview: Joubert Syndrome (JS) is a rare, genetically heterogeneous, autosomal recessive neurodevelopmental disorder classified under the umbrella of ciliopathies. It is characterized by a pathognomonic mid-hindbrain malformation known as the "molar tooth sign" (MTS) on magnetic resonance imaging (MRI). The MTS results from hypoplasia or agenesis of the cerebellar vermis, an abnormally deep interpeduncular fossa, and thickened, elongated superior cerebellar peduncles. The core clinical features of JS include hypotonia in infancy, global developmental delay, ataxia, and variable degrees of intellectual disability. Additionally, patients often present with abnormal breathing patterns, such as episodic tachypnea or apnea, and abnormal eye movements, particularly oculomotor apraxia. Beyond the neurological manifestations, JS is a multisystem disorder that can affect various other organs, reflecting the ubiquitous nature of primary cilia throughout the body. The clinical spectrum is broad and includes several subtypes based on the specific organ systems involved. These subtypes include JS with retinal disease (JS-Ret), JS with renal disease (JS-Ren), JS with oculorenal disease (JS-OR), JS with hepatic disease (JS-H), and JS with oral-facial-digital features (JS-OFD). The retinal involvement typically manifests as a progressive retinal dystrophy, which can range from congenital blindness (Leber congenital amaurosis-like) to a later-onset retinitis pigmentosa-like phenotype. The clinical significance of JS lies in its complex, multiorgan nature, which requires a multidisciplinary approach to diagnosis and management. The prognosis and mortality are largely dependent on the severity of the extra-neurological manifestations, particularly renal and hepatic disease. The primary OMIM phenotypic entry for Joubert Syndrome 1 is 213300, with numerous other OMIM entries corresponding to specific genetic subtypes (e.g., JBTS2 through JBTS37). The Orphanet number for isolated Joubert syndrome is ORPHA:475.

Patient and family guide: Joubert Syndrome is a rare genetic condition that affects the development of the brain, specifically an area called the cerebellum, which controls balance and coordination. Children born with this condition often have low muscle tone (hypotonia), developmental delays, and difficulty coordinating their movements (ataxia). They may also have unusual breathing patterns, such as breathing very fast or stopping breathing for short periods, especially when they are babies. A key feature that doctors look for to diagnose Joubert Syndrome is a specific shape in the brain seen on an MRI scan, which is called the "molar tooth sign" because it looks like a tooth. In addition to affecting the brain, Joubert Syndrome can also impact other parts of the body, including the eyes, kidneys, and liver. Many individuals with this condition develop vision problems due to a condition called retinal dystrophy, where the light-sensitive layer at the back of the eye (the retina) slowly breaks down. This can cause difficulty seeing in the dark, a narrowing of the field of vision, and in some cases, severe vision loss or blindness from a young age. Other eye issues like crossed eyes (strabismus), droopy eyelids (ptosis), and jerky eye movements (nystagmus) are also common. Because Joubert Syndrome can affect multiple organs, it is important for patients to have regular check-ups with a team of different doctors, including eye specialists, kidney doctors, and neurologists. While there is currently no cure for the condition, treatments like physical, occupational, and speech therapy can help children reach their full potential. Regular monitoring of the eyes, kidneys, and liver is crucial to catch and manage any complications early, helping to improve the quality of life for individuals with Joubert Syndrome.

Symptoms and clinical features: The clinical presentation of Joubert Syndrome is characterized by a triad of core neurological features, along with variable multiorgan involvement. In the early stages (neonatal period and early infancy), the most prominent symptoms are hypotonia (low muscle tone), abnormal respiratory patterns, and abnormal eye movements. The respiratory abnormalities often manifest as episodic tachypnea (rapid breathing) alternating with apnea (pauses in breathing), which can be life-threatening but typically improve as the child grows. Ocular motor abnormalities are common and include oculomotor apraxia (difficulty initiating voluntary eye movements), nystagmus (involuntary jerky eye movements), and strabismus (crossed eyes). As the child progresses into the intermediate stages (toddler and childhood years), the hypotonia often evolves into truncal ataxia, leading to a staggering gait and poor balance. Global developmental delay becomes evident, with significant delays in achieving motor milestones such as sitting, standing, and walking. Speech and language development are also frequently delayed, often complicated by oral motor apraxia. Cognitive impairment is common, ranging from mild learning disabilities to severe intellectual disability, although some individuals have normal intelligence. During this stage, the signs of retinal dystrophy may become apparent, presenting as decreased visual acuity, photophobia, or nyctalopia (night blindness). In the advanced stages (adolescence and adulthood), the neurological symptoms generally stabilize and are non-progressive. However, the extra-neurological manifestations can progress and become the primary source of morbidity. In patients with retinal involvement, the retinal dystrophy may progress to severe visual impairment or blindness. Renal disease, particularly nephronophthisis, can progress silently and present with polyuria and polydipsia before advancing to end-stage renal disease, requiring dialysis or transplantation. Hepatic fibrosis can lead to portal hypertension, hepatosplenomegaly, and gastroesophageal varices. Skeletal abnormalities, such as polydactyly and scoliosis, may also require ongoing management.

Molecular pathology: Joubert Syndrome is classified as a ciliopathy, a group of disorders caused by defects in the primary cilium. The primary cilium is a specialized, non-motile, microtubule-based organelle that projects from the surface of most mammalian cells. It acts as a sensory antenna, playing crucial roles in sensing the extracellular environment, transducing chemical and mechanical signals, and regulating various developmental and homeostatic signaling pathways, such as Sonic Hedgehog (Shh) and Wnt signaling. The proteins encoded by JS-associated genes localize to different compartments of the primary cilium, including the basal body, the transition zone, and the axoneme. For example, CEP290 and RPGRIP1L are key components of the transition zone, which functions as a gatekeeper to regulate the entry and exit of proteins into the ciliary compartment. AHI1 localizes to the basal body and is involved in vesicular trafficking to the cilium. Mutations in these genes disrupt the structural integrity or functional capacity of the primary cilium, leading to impaired ciliogenesis, defective protein trafficking, or aberrant signal transduction. In the retina, the connecting cilium of photoreceptor cells is a specialized primary cilium essential for the transport of opsins and other phototransduction proteins from the inner segment to the outer segment. Defects in JS proteins, particularly CEP290 and AHI1, compromise this transport mechanism. The failure to properly traffic and localize essential proteins leads to the accumulation of proteins in the inner segment, disruption of outer segment formation, and ultimately, the degeneration and death of photoreceptor cells. This cellular dysfunction manifests clinically as retinal dystrophy, ranging from congenital blindness to progressive retinitis pigmentosa.

Genetics: Joubert Syndrome is a genetically heterogeneous disorder, primarily inherited in an autosomal recessive pattern, with rare cases (such as those caused by mutations in the OFD1 gene) following an X-linked recessive pattern. To date, mutations in over 35 genes have been identified as causative for JS, accounting for 60% to 90% of cases. These genes encode proteins that are essential for the structure, function, and maintenance of primary cilia, classifying JS as a ciliopathy. The known causative genes for JS include: AHI1, ARL13B, ARL3, ARMC9, B9D1, B9D2, C2CD3, CC2D2A, CEP104, CEP120, CEP290, CEP41, CPLANE1 (C5orf42), CSPP1, INPP5E, KIAA0586, KIF7, MKS1, NPHP1, NPHP3, OFD1, PDE6D, PIBF1, POC1B, RPGRIP1L, SUFU, TCTN1, TCTN2, TCTN3, TMEM107, TMEM138, TMEM216, TMEM231, TMEM237, and TMEM67. Mutations in CEP290 are among the most common, implicated in approximately 10% of all JS cases and up to 50% of cases with severe retinal involvement. Genotype-phenotype correlations are significant in JS, particularly regarding retinal and renal involvement. For instance, mutations in CEP290, AHI1, and INPP5E are strongly associated with early and aggressive retinal degeneration. Conversely, mutations in NPHP1 are frequently linked to progressive kidney disease (nephronophthisis). Some genes, such as TMEM67, are more commonly associated with hepatic fibrosis. However, there is considerable clinical variability even among individuals with the same genetic mutation, suggesting the influence of modifier genes or environmental factors.

Diagnostic evaluation: The diagnosis of Joubert Syndrome (JS) is primarily based on the presence of a pathognomonic neuroradiological hallmark known as the "molar tooth sign" (MTS) on brain magnetic resonance imaging (MRI). The MTS is characterized by an abnormally deep interpeduncular fossa, prominent, straight, and thickened superior cerebellar peduncles, and hypoplasia of the cerebellar vermis. High-quality MRI with thin (≤3 mm) axial cuts through the posterior fossa from the midbrain to the pons, along with standard axial, coronal, and sagittal cuts, is recommended to accurately identify the MTS. Clinical diagnostic criteria also include hypotonia in infancy, developmental delay, and one or both of the following: irregular breathing patterns (episodic tachypnea and/or apnea) and abnormal eye movements, particularly oculomotor apraxia. Ophthalmologic evaluation is crucial for diagnosing the retinal involvement in JS. Fundoscopy and fundus autofluorescence imaging can reveal signs of retinal dystrophy, which may range from early-onset severe rod-cone dystrophy (Leber congenital amaurosis-like) to late-onset cone-rod dystrophy. Other ocular findings may include chorioretinal coloboma, optic nerve atrophy, and abnormal retinal pigmentation. Electroretinogram (ERG) studies are often abnormal in JS patients with retinal involvement, showing severely reduced or non-recordable responses, particularly in those with mutations in genes such as CEP290, CEP164, AHI1, MKS1, and INPP5E. Genetic testing plays a significant role in confirming the diagnosis and determining the specific subtype of JS. Targeted multigene panels that include the known JS-associated genes can identify the genetic cause in 60% to 90% of cases. If targeted testing is negative, exome or whole-genome sequencing may be considered. Differential diagnosis includes other cerebellar vermis malformations without the MTS (e.g., Dandy-Walker malformation), X-linked cerebellar hypoplasia, Meckel-Gruber syndrome, Bardet-Biedl syndrome, and isolated Leber congenital amaurosis. Careful clinical and genetic evaluation is necessary to distinguish JS from these related ciliopathies and other neurodevelopmental disorders.

Differential diagnosis: Differential diagnosis of Joubert syndrome includes: (1) Dandy-Walker malformation — posterior fossa cyst, no molar tooth sign. (2) Meckel-Gruber syndrome — occipital encephalocele, polydactyly, cystic kidneys; lethal; overlapping genes with JS. (3) COACH syndrome — JS with hepatic fibrosis (Cerebellar vermis hypoplasia, Oligophrenia, Ataxia, Coloboma, Hepatic fibrosis). (4) Senior-Løken syndrome — retinal dystrophy with nephronophthisis, may lack molar tooth sign. (5) Dekaban-Arima syndrome — JS with cystic kidneys and hepatic fibrosis. (6) Oral-facial-digital syndrome type VI — JS features with oral frenula, tongue hamartomas.

Natural history: The natural history of Joubert Syndrome is highly variable and depends significantly on the specific genetic mutation and the extent of multiorgan involvement. The disease onset is typically antenatal, with clinical presentation often occurring in the neonatal period or early infancy. Initial signs frequently include hypotonia, abnormal breathing patterns (episodic tachypnea and/or apnea), and abnormal eye movements such as oculomotor apraxia. As the child grows, the hypotonia often evolves into truncal ataxia, and delayed acquisition of motor milestones becomes evident. The progression of the disease is largely determined by the involvement of organs other than the central nervous system. The neurological deficits, including ataxia and intellectual disability, are generally non-progressive. In fact, some features, such as the abnormal breathing patterns and oculomotor apraxia, may improve with age. However, the retinal, renal, and hepatic manifestations can be progressive and significantly impact the prognosis. Retinal dystrophy in JS can present as early-onset severe rod-cone dystrophy, leading to congenital or early childhood blindness, or as a more slowly progressive cone-rod dystrophy that results in declining visual acuity and night blindness over time. Renal disease, particularly nephronophthisis, often presents in the first or second decade of life with a urine-concentrating defect and can progress to end-stage renal disease (ESRD) by the teenage years. Hepatic fibrosis is usually progressive and can lead to portal hypertension and its complications. Regular monitoring of these organ systems is essential for managing the progressive aspects of the syndrome.

Management and treatment research: ### Current Management and Standard of Care Joubert syndrome is a genetic condition in the ciliopathy group of disorders. Ciliopathies result from changes affecting cilia—small structures that help cells communicate and function. There is currently no treatment that corrects the underlying genetic cause or reliably prevents progression of all features of Joubert syndrome. Care is individualized and often coordinated among specialists because Joubert syndrome may affect the brain, eyes, kidneys, liver, breathing, and other organs. Management may include: - **Developmental and rehabilitation services:** Early-intervention programs, physical therapy, occupational therapy, and speech-language therapy can support low muscle tone (hypotonia), balance and coordination difficulties (ataxia), feeding challenges, and developmental delays. - **Educational and behavioral support:** Neurodevelopmental assessments and individualized education plans can help identify learning needs and appropriate school supports. - **Breathing and sleep care:** Infants and young children may have unusual breathing patterns, including apnea (pauses in breathing). Respiratory or sleep evaluation may be needed, particularly in early childhood. - **Eye and vision care:** Regular ophthalmology examinations are important to monitor for retinal dystrophy and other eye findings. Care may include glasses for refractive errors, treatment of strabismus (eye misalignment) or ptosis (drooping eyelid), and low-vision services. Assistive technology, orientation and mobility training, and specialized educational resources can support people with reduced vision. - **Kidney and liver monitoring:** Some people develop kidney disease, liver fibrosis, or related complications. Monitoring may include kidney-function testing, blood pressure checks, liver assessments, and imaging based on symptoms and the person’s genetic diagnosis. Advanced kidney disease may require dialysis or kidney transplantation. Severe liver disease requires specialist care and, rarely, transplantation. - **Other specialty care:** Depending on individual needs, care may involve neurology, nephrology, gastroenterology/hepatology, endocrinology, orthopedics, genetics, and other specialists. ### Approved Therapies There are no approved disease-modifying therapies specifically for Joubert syndrome or Joubert syndrome–associated retinal disease. Treatment focuses on monitoring, supportive care, rehabilitation, and timely management of organ-specific complications. ### Investigational Therapies There are no Joubert syndrome–specific investigational treatment programs listed in the current treatment pipeline data. Research in ciliopathies and inherited retinal diseases more broadly includes gene-based approaches, RNA-targeted medicines, and treatments intended to protect retinal cells. However, these approaches are not established treatments for Joubert syndrome and may not apply to every genetic cause of the condition. ### Clinical Trial Participation The currently listed recruiting studies are not necessarily designed specifically for Joubert syndrome. Eligibility depends on a person’s genetic findings, symptoms, age, medical history, and the study site’s criteria. - **NCT01401998 — ARPKD Database Study:** A recruiting observational database study led by Children’s Hospital of Philadelphia. Autosomal recessive polycystic kidney disease (ARPKD) can involve kidney and liver features that overlap with some ciliopathies. Participation may be relevant for selected individuals with related kidney or liver findings. - **NCT06111950 — Study of the Pathophysiology of RNU4ATAC and RTTN Associated Syndromes:** A recruiting study led by Hospices Civils de Lyon. This study is focused on syndromes associated with changes in the **RNU4ATAC** or **RTTN** genes and may be relevant only to people with one of these genetic findings. Families considering research participation can discuss genetic test results and possible eligibility with their treating specialist or a genetic counselor.

Outlook: The prognosis for individuals with Joubert Syndrome is highly variable and depends primarily on the severity of the organ systems involved. The neurological deficits, such as ataxia and intellectual disability, are generally non-progressive, and some features like abnormal breathing and oculomotor apraxia may even improve with age. However, the presence and progression of extra-neurological manifestations, particularly renal and hepatic disease, significantly impact life expectancy and quality of life. Progression to end-stage renal disease is a leading cause of mortality in JS patients after the first year of life. Visual outcomes in JS patients with retinal dystrophy vary depending on the specific genetic mutation. Those with early-onset severe rod-cone dystrophy may experience congenital or early childhood blindness, while others may have a more slowly progressive decline in visual acuity and visual field. The visual impairment, combined with motor and cognitive delays, can significantly affect the individual's independence and quality of life. Early intervention with supportive therapies, special education programs, and regular monitoring of multiorgan complications are essential for optimizing outcomes and improving the quality of life for patients and their families.

Epidemiology: The prevalence of Joubert Syndrome is estimated to be between 1 in 80,000 and 1 in 100,000 live births. However, this figure may be an underestimate due to underdiagnosis or misdiagnosis of milder or atypical cases. A population-based study in Italy demonstrated an overall crude prevalence rate of 0.47 per 100,000 population. There are notable geographic and ethnic variations in the prevalence of JS. Higher prevalence rates have been observed in specific populations, including French Canadians, the Dutch, Ashkenazi Jews, Canadian Hutterites, and the Japanese. These variations are often attributed to founder effects and higher rates of consanguinity in certain communities, which increase the likelihood of autosomal recessive inheritance. No significant sex differences in prevalence have been consistently reported.

Selected references: 1. Parisi MA, Glass IA. Joubert Syndrome. 2003 Jul 9 [Updated 2017 Jun 29]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. PMID: 20301500 2. Wang SF, Kowal TJ, Ning K, Koo EB, Wu AY, Mahajan VB, Sun Y. Review of Ocular Manifestations of Joubert Syndrome. Genes (Basel). 2018 Dec 4;9(12):605. PMID: 30518138 3. Brancati F, Dallapiccola B, Valente EM. Joubert Syndrome and related disorders. Orphanet J Rare Dis. 2010 Jul 8;5:20. PMID: 20615230 4. Gana S, et al. Genotype-phenotype correlates in Joubert syndrome. Am J Med Genet C Semin Med Genet. 2022;190(1):72-88. PMID: 35238148 5. Nuovo S, et al. Age and sex prevalence estimate of Joubert syndrome in Italy. Neurology. 2020;94(8):e797-e801. PMID: 31941793 6. Brooks BP, et al. Joubert Syndrome: Ophthalmological Findings in Correlation with Genotype and Renal Function. Ophthalmology. 2018;125(12):1937-1946. PMID: 29934055